ストックスクリーナーアプリを入手
1.68
1.75%
-0.03
アフターアワーズ：
1.74
0.06
+3.57%
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com
BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia
BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada
Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener
ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks
BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz
BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World
BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com
BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India
Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - MarketScreener
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN
BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia
BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com
BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks
BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire
Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan
1.00%
大文字化:
|
ボリューム (24 時間):